Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant,
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Epidermal growth factor receptor ( Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; Addition of pembrolizumab to chemotherapy in patients with TKI-resistant,
Identifiants
pubmed: 39173098
doi: 10.1200/JCO.23.02747
doi:
Banques de données
ClinicalTrials.gov
['NCT03515837']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM